Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development - Seite 2

Q&A: Reggie Ewesuedo, MD

Reggie Ewesuedo, MD, is Vice President of Clinical Development at Lantern Pharma. Dr. Ewesuedo has more than 20 years of expertise in drug development research activities and has served in clinical research lead capacities at The Ohio State University, AstraZeneca, Genzyme, Sanofi, Pfizer, Tesaro/GlaxoSmithKline, and Kymera.

May’s Webinar Wednesday

May 29, 2024 – 1:00pm Eastern
“LP-184 in Pancreatic Cancer and Other Solid Tumors”
Register here: https://bit.ly/3U9NizL

Join Igor Astsaturov, MD and Kishor Bhatia, PhD to explore the science of pancreatic cancer and other solid tumors, challenges around diagnosis and treatments of the disease, and LP-184 as a promising agent for these tumors with ongoing Phase 1 trial and multiple preclinical validations.

Presentation: Igor Astsaturov, MD

Igor Astsaturov, MD is a leading expert in pancreatic cancer collaborating with Lantern Pharma on the LP-184 clinical trial. Dr. Astsaturov is an Associate Professor in the Department of Hematology/Oncology, Co-Director of the Marvin & Concetta Greenburg Pancreatic Cancer Institute, and Inaugural Holder of the Paul F. Engstrom Professorship in Oncology.

Q&A: Kishor Bhatia, PhD

Kishor Bhatia, PhD, is Chief Scientific Officer at Lantern Pharma. Kishor brings more than 40 years of experience in cancer research, which has included roles such as Director of the Children’s Cancer Center Riyadh and Director of the Office of AIDS Malignancy Program at the National Cancer Institute (NCI).

_________________

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program.